Brio Consultants’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$581K Buy
484
+26
+6% +$26.6K 0.07% 101
2026
Q1
$453K Buy
458
+31
+7% +$31.4K 0.06% 104
2025
Q4
$459K Buy
427
+11
+3% +$10.5K 0.06% 102
2025
Q3
$318K Buy
416
+45
+12% +$33.5K 0.04% 108
2025
Q2
$290K Buy
371
+82
+28% +$63.7K 0.04% 108
2025
Q1
$239K Buy
289
+25
+9% +$20.8K 0.04% 104
2024
Q4
$204K Buy
+264
New +$219K 0.03% 109

Other funds holding LLY

Brio Consultants's LLY Position: Q2 2026 in Review

Brio Consultants increased its Eli Lilly (LLY) stake by 5.7% in Q2 2026, buying an estimated $26.6K and bringing the position to 484 shares worth $581K. The position accounts for 0.07% of the portfolio, ranked #101.

Brio Consultants first reported a position in LLY in Q4 2024 and has held it in 7 quarters since. 4,626 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Brio Consultants held 484 shares of Eli Lilly worth $581K as of Q2 2026.
  • Brio Consultants bought 26 Eli Lilly shares in Q2 2026, an estimated $26.6K.
  • Eli Lilly made up 0.07% of Brio Consultants's portfolio in Q2 2026, its #101 holding.
  • Brio Consultants first reported a position in Eli Lilly in Q4 2024 and has held it in 7 quarters since.
  • 4,626 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Brio Consultants's 13F filing for Q2 2026, filed 12 Aug 2026.